ARE&M · NSE India · United States
are.comFinancials as of FY2025
Owns purpose-built laboratory buildings in top biotech neighborhoods and also invests in the drug companies renting those buildings.
Alexandria Real Estate Equities owns laboratory buildings in a handful of established biotech clusters — Kendall Square, South San Francisco, San Diego — where the fume hoods, autoclave systems, and chemical waste handling are built into the structure at construction, making each building FDA-qualifiable for pharmaceutical manufacturing. Because FDA qualification is tied to a specific site and its equipment, a tenant that wanted to move would have to restart a multi-year re-qualification process before it could legally manufacture in a new facility, so the physical specification of the building is what keeps tenants in place for the long term. On top of that, Alexandria's venture capital arm co-invests in the same tenant companies that pay it rent, which means a startup receiving co-investment gets steered toward in-cluster lab space, and those leasing relationships in turn generate the next round of proprietary deal flow — a loop that a standalone REIT without a VC arm, or a standalone VC fund without captive laboratory inventory, cannot replicate. The same alignment that suppresses tenant churn during normal conditions becomes a vulnerability in a biotech downturn: if a cohort of co-invested companies fails at once, the lease vacancies and the equity write-downs land on the same balance sheet at the same moment, and the specialized space they leave behind cannot be quickly filled because any replacement tenant must also pass FDA facility qualification before moving in.
How does this company make money?
Tenants pay rent every month under triple-net leases, which means they also cover operating expenses and property taxes on top of the base rent — so the company keeps most of what it collects. When the drug companies it has co-invested in grow in value or are acquired, the company earns returns on those equity stakes. It also collects reimbursements from tenants for the specialized laboratory buildouts it funds upfront, with those costs paid back gradually over the life of the lease.
What makes this company hard to replace?
The fume hoods, autoclave systems, and chemical waste handling built into these buildings cannot be quickly rebuilt somewhere else. Even if a competing space became available, a pharmaceutical tenant would have to go through a multi-year FDA qualification process before it could legally use that facility for manufacturing. On top of that, tenants who received co-investment from the company's venture capital arm have existing relationships with the leasing and investment ecosystem that would be difficult to replicate with a new landlord.
What limits this company?
The land available for new laboratory buildings inside Kendall Square and South San Francisco has run out. No amount of money can create more developable parcels in those neighborhoods. That means every new biotech company that wants space in those clusters has to compete for what already exists, and existing tenants are unlikely to leave because moving would force them through a multi-year FDA re-approval process.
What does this company depend on?
The company cannot operate without municipal permits from Cambridge, San Francisco, and San Diego that allow laboratory-grade chemical waste systems in its buildings. It also relies on specialized HVAC contractors who know how to install biosafety-level containment systems, investment-grade debt markets to refinance the loans used to construct those buildings, FDA-compliant laboratory design standards that define what pharmaceutical tenants need, and venture capital co-investment partners who help fund life science startups.
Who depends on this company?
Biotech startups in Greater Boston and the Bay Area depend on it for laboratory space built specifically for drug discovery research — without it, those companies would struggle to find anywhere suitable to work. Pharmaceutical companies running clinical trials would face significant delays if they had to move their specialized manufacturing equipment to a different facility. Life science employers in Research Triangle would find it harder to attract skilled researchers if nearby laboratory infrastructure did not exist.
How does this company scale?
Once engineering standards for a laboratory building type are established, the design and tenant improvement specifications can be reused for new developments without starting from scratch. But geographic expansion is slow because the company's model only works in places where research universities, venture capital, and large pharmaceutical companies are already clustered together — and there are very few such places.
What external forces can significantly affect this company?
If the FDA changes its pharmaceutical manufacturing requirements, existing laboratory buildings may need costly retrofits to stay compliant. Federal research funding levels directly affect how many biotech startups form near university campuses, which drives demand for the company's space. Changes to H-1B visa policy could reduce the supply of life science researchers available to work in the company's target markets, shrinking the pool of companies that need laboratory space.
Where is this company structurally vulnerable?
If a large number of the co-invested startups failed at the same time — which is more likely during a broad biotech funding downturn — the company would take a financial hit on its investment portfolio and simultaneously lose rent-paying tenants from its buildings. Both losses would land on the same balance sheet at once. Replacing those tenants would be slow because any new pharmaceutical company moving in would need to go through its own FDA facility qualification process before it could operate.
Sign in to view price data.
Sign inScreen for dividend patterns
Find other stocks with similar dividend characteristics in the screener.
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Companies that share the same coordination system — how they create, deliver, or capture value.
CompanyGraph